Comparison of the effectiveness and complications of Desferal and Desphonac in thalassemic patients

A comparative study on the effectiveness and complications of Desferal and Desphonac in thalassemic patients in Kermanshah 2018-2019

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N117

Enrollment

Registered

2019-03-17

Start date

2019-03-11

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia. Beta thalassemia

Interventions

Intervention 1: The first intervention group will receive desferal for 8 consecutive days in the weekend for five consecutive days through the pump. Intervention 2: The second intervention group will

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with intermedia and major thalassemia

Exclusion criteria

Exclusion criteria: Renal patients Patients with hypertension, skin diseases, liver complications, and respiratory and auditory diseases

Design outcomes

Primary

Measure	Time frame
Respiratory status. Timepoint: Beginning of the study and end of the study (three months later). Method of measurement: According to clinical symptoms and asking patients.;Digestive complications. Timepoint: Beginning of the study and end of the study (three months later). Method of measurement: According to symptoms and asking patients.;Skin complications. Timepoint: Beginning of the study and end of the study (three months later). Method of measurement: According to clinical symptoms and asking patients.;Renal and hepatic complications. Timepoint: Beginning of the study and end of the study (three months later). Method of measurement: blood test.	—

Measure

Time frame

Respiratory status. Timepoint: Beginning of the study and end of the study (three months later). Method of measurement: According to clinical symptoms and asking patients.;Digestive complications. Timepoint: Beginning of the study and end of the study (three months later). Method of measurement: According to symptoms and asking patients.;Skin complications. Timepoint: Beginning of the study and end of the study (three months later). Method of measurement: According to clinical symptoms and asking patients.;Renal and hepatic complications. Timepoint: Beginning of the study and end of the study (three months later). Method of measurement: blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Nargece Soraya

Kermanshah University of Medical Sciences

nargece.soraya@kums.ac.ir+98 83 3721 8202

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026